Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer (NCT07590934)

🧪 Interventions in This Study

• AZD2265 (FPI-2265) (DRUG)
• Palacaparib (AZD9574) (DRUG)
• Docetaxel (DRUG)
• AZD2287 (Imaging agent) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (37 Sites)

Showing the first 25 of 37 sites.

• Research Site — Duarte, California
• Research Site — Encino, California
• Research Site — South Pasadena, California
• Research Site — Miami, Florida
• Research Site — Tampa, Florida
• Research Site — Metairie, Louisiana
• Research Site — Minneapolis, Minnesota
• Research Site — Omaha, Nebraska
• Research Site — New York, New York
• Research Site — Portland, Oregon
• Research Site — Houston, Texas
• Research Site — North Adelaide,
• Research Site — Essen,
• Research Site — Jena,
• Research Site — Rostock,
• Research Site — Tübingen,
• Research Site — Bergamo,
• Research Site — Meldola,
• Research Site — Milan,
• Research Site — Milan,
• Research Site — Roma,
• Research Site — Seoul,
• Research Site — Seoul,
• Research Site — Seoul,
• Research Site — Seoul,

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Prostate Cancer

• Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC — Boston, Massachusetts
• PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer — Boston, Massachusetts
• Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer — Detroit, Michigan
• Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer — Basking Ridge, New Jersey
• Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers — New York, New York
• Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC — Tucson, Arizona

Explore by condition: All Metastatic Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.